Citi raised the firm’s price target on Sotera Health (SHC) to $21 from $17 and keeps a Neutral rating on the shares. The firm adjusted models in the life science tools and diagnostics group ahead of the Q3 reports.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SHC: